logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences: Transformational potential

Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by TILS for nasal and oral administration. These ground-breaking approaches can not only reduce the toxicity seen with systemic treatment they may also be more efficacious than standard injected biologics. Broadly, if clinical study outcomes are positive, this can potentially revolutionise treatment in the mAbs market which has a projected value over $130bn by 2025, comprising the best-selling drugs in the world.

The company is also accelerating the development of TZLS-501, a fully human anti-IL6R mAb, towards the clinic for COVID-19 treatment. The innovative delivery route via handheld nebulizer or inhaler to the lung, directly targets the main site of inflammation.

 

 

 

TILS is moving the development plan aggressively aiming for IND filing for TZLS-501 for treating COVID-19 respiratory complications in Q1 21. To our knowledge TILS is a pioneer in developing anti-IL-6R mAbs for administration via a nebulizer or inhaler direct to the lungs and has filed a patent on the approach. Also, TZLS-501 showed attractive preclinical anti-inflammatory mechanisms vs market leading anti-IL6R mAb Actemra (Roche), which is being developed for COVID. This could lead to efficacy at lower doses. These factors suggest TZLS-501 can have significant clinical and commercial differentiation. Urgent unmet need means that development of TZLS-501 could be accelerated, possibly leading to its widespread supply for investigational use. the EC recently signed with Roche to supply sufficient quantities of Actemra to the 27 member states for studies.

Quick facts: Tiziana Life Sciences PLC

Price: 85 GBX

AIM:TILS
Market: AIM
Market Cap: £165.42 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

on 22/9/20

57 min read